GLP-1-SM

GLP-1-SM (Semaglutide) is a synthetic GLP-1 receptor agonist peptide with structural modifications conferring extended duration of action. It is studied in research for its GLP-1R binding kinetics, incretin signaling dynamics, and metabolic pathway modulation in preclinical models.

Semaglutide is a long-acting GLP-1 receptor agonist peptide engineered for extended duration of action through fatty acid acylation and amino acid substitutions. It is studied in research for GLP-1R signaling dynamics and incretin pathway biology. Supplied as a lyophilized research peptide.

Semaglutide was developed through systematic optimization of the GLP-1 peptide backbone, incorporating amino acid substitutions and a C-18 fatty diacid chain for albumin binding. This engineering approach extended its pharmacokinetic profile compared to native GLP-1. Published research has extensively characterized its receptor pharmacology and signaling properties.

Published preclinical research demonstrates that Semaglutide binds GLP-1R with high affinity and activates cAMP-dependent signaling cascades. Studies have characterized its effects on glucose-dependent insulin secretion, glucagon suppression, and gastric motility signaling in research models. Its extended pharmacokinetic profile due to albumin binding and DPP-4 resistance has been well documented.